Figure 2.

Sensitivity analysis. The sensitivity analysis estimated the minimum difference in panitumumab concentration between antibody-positive and antibody-negative samples that could be statistically significant (P < 0.05) with respect to the model prediction. Results show that the current observed sample size for pharmacokinetic testing (n = 38) from antibody-positive patients was only adequate to detect a difference of > 55%. Approximately 200 and 650 samples from antibody-positive patients would be required to detect differences of 38% and 20%, respectively.

Weeraratne et al. BMC Clinical Pharmacology 2011 11:17   doi:10.1186/1472-6904-11-17
Download authors' original image